Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2022 16:05 ET | Source: Immunovant

Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
May 19, 2022 16:05 ET | Source: Immunovant

Immunovant to Present at the UBS Global Healthcare Conference on May 23rd

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
May 04, 2022 08:00 ET | Source: Immunovant

Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
March 28, 2022 07:00 ET | Source: Immunovant

Immunovant to Host Virtual R&D Day on March 30, 2022

NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
February 09, 2022 08:00 ET | Source: Immunovant

Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
February 04, 2022 07:00 ET | Source: Immunovant

Immunovant Reports Financial Results for the Quarter Ended December 31, 2021

NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
January 25, 2022 08:30 ET | Source: Immunovant

Immunovant Appoints Mark Levine as Chief Legal Officer

Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25,...
January 07, 2022 14:07 ET | Source: Immunovant

Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
December 30, 2021 07:00 ET | Source: Immunovant

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases,...
November 12, 2021 12:18 ET | Source: Immunovant

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...